Swedan-based Qbtech has obtained the US Food and Drug Administration (FDA) approval for the QbTest, a neuropsychological test designed to aid in the evaluation of treatment interventions in patients with ADHD.

Qbtech claims that QbTest is the only test in the world cleared by the FDA for treatment evaluation within ADHD. The computer-based test provides clinicians with objective and unbiased decision-making support when diagnosing and treating ADHD in children, adolescents and adults.

QbTest measures the three core signs of ADHD – hyperactivity, inattention and impulsivity – in children, adolescents and adults. QbTest combines a test of attention ability with a movement analysis based on an infrared measurement system.

Qbtech CEO Carl Reuterskiöld noted that the QbTest enables clinicians to better determine effects of treatment and to reduce the risk of over- and undermedication of patients, explains.

Test results for the QbTest are presented in a report and compared with norm data from a group of people of the same sex and age who do not have ADHD.